Form 4 for CRL Charles River Laboratories
Accepted 2023-01-04 00:00:00 ET · period of report 2023-01-03 · accession 0001127602-23-000743 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-04 | 2023-01-03 | CRL | Thompson Craig B. | Dir | A - Grant | $0.00 | +244 | 244 | New | $0 |
| D | 2023-01-04 | 2023-01-03 | CRL | Thompson Craig B. | Dir | A - Grant | $218.40 | +592 | 592 | New | +$129.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-03 | A | A | 244 | $0.00 | 244 | D | — | — | (F1) Consists of 244 unvested restricted stock units that vest on 1/03/2024. |
| 2 | Derivative | Stock Options (Right to Buy) | 2023-01-03 | A | A | 592 | $218.40 | 592 | D | $218.40 · 2024-01-03 to 2033-01-03 | 592 Common Stock | (F2) The Stock Options become exercisable 1/03/2024. |